Inotiv Inc
NOTV
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.79M
Close$
$-1.87
2438.4% downside
Current Fair Value
2438.4% downsideOvervalued by 2438.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.79 Million |
|---|---|
| Enterprise Value | $497.86 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.11 |
| Beta | 4.08 |
| Outstanding Shares | 34,653,000 |
Return
| Return on Equity | -112.81% |
|---|---|
| Return on Assets | -12.38% |
| Return on Invested Capital | -23.81% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.04 |
| Enterprise Value to Revenue | 0.98 |
| Enterprise Value to EBIT | -12.9 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 1.02 |
| Debt to Equity | 6.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
$136.68 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 90.91% |
|---|---|
| Total Calls | 36,100▲ 228.18% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.87%▼ 8.16% |
|---|---|
| Total Invested | $1.30M▼ 69.47% |
| Investors Holding | 51▼ 7.00% |
ESG Score
No data
About Inotiv Inc
409 employees
CEO: Jacqueline Lemke Bioanalytical Systems, Inc., operating as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development compa...